Trial Profile
Durvalumab Plus Tremelimumab Combination Immunotherapy With or Without Weekly Paclitaxel in Patients With Advanced Biliary Tract Carcinoma (BTC) After Failure of Platinum-based Chemotherapy: a Randomized Non-comparative Two-arm Phase II Study
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 09 Jan 2024
Price :
$35
*
At a glance
- Drugs Durvalumab (Primary) ; Paclitaxel (Primary) ; Tremelimumab (Primary)
- Indications Biliary cancer
- Focus Therapeutic Use
- Acronyms IMMUNO-BIL; IMMUNOBIL PRODIGE 57
- 04 Jan 2024 Status changed from recruiting to active, no longer recruiting.
- 06 Mar 2023 Planned End Date changed from 31 Dec 2022 to 31 Dec 2024.
- 07 Jun 2022 The protocol was amended to modify the T schedule (300 mg at cycle 1 [T300], amended Arm A) due to higher efficacy reported in other tumors as compared to T75 mg x 4. The new primary endpoint was the overall survival (OS) rate at 6 months (M6) in amended Arm A (D + T300) with a Fleming two-stage design .